免疫检查点抑制剂在自身免疫性疾病患者抗肿瘤治疗中的应用

Immune checkpoint inhibitors for autoimmune disease patients with advanced cancer

免疫检查点抑制剂在多种肿瘤的治疗中取得了显著疗效,但自身免疫性疾病患者常因自身复杂的免疫情况被排除在免疫检查点抑制剂的临床试验之外。本文将从细胞毒性T淋巴细胞相关抗原-4单抗和程序性死亡蛋白-1/程序性死亡蛋白配体-1单抗的作用机制入手,分析检查点抑制剂在自身免疫性疾病患者临床抗肿瘤治疗中的安全性和有效性,探讨更加有效的治疗方案及免疫检查点抑制剂疗效的可能影响因素,为临床实践提供依据。

Immune checkpoint inhibitors have been shown to be effective in the treatment of a variety of tumors,but patients with autoimmune diseases are often excluded from clinical trials of immune checkpoint inhibitors because of their complex immune conditions.Starting with the mechanism of cytotoxic T lymphocyte associated antigen-4(CTLA-4)blockade and programmed death-1/programmed cell death ligand-1(PD-1/PD-L1)blockade,this article will analyze the safety and effectiveness of checkpoint inhibitors in the treatment of tumors in patients with autoimmune diseases,explore more effective treatment options and the possible influencing factors of the efficacy of checkpoint inhibitors,so as to provide evidence for clinical practice.